AK137 for advanced solid tumors that stopped responding to treatment
Part of Cancer clinical trials.
This trial tests a new drug called AK137, which is a type of 'bispecific antibody' that targets two proteins (CD73 and LAG-3) to help your own immune system fight the cancer. It may be an option if your cancer has stopped responding to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced or metastatic cancer that has stopped responding to standard treatment, or for which no standard treatment exists.
- Your cancer must be measurable (a tumor that can be seen on scans).
- You need to be in fairly good health, able to take care of yourself (ECOG 0 or 1), and have a life expectancy of at least 3 months.
- You cannot have had previous treatment with drugs that specifically target CD73 or LAG-3.
- If you had prior immunotherapy, you must have recovered from any side effects, and it must not have been stopped due to severe toxicity.
- You must not have had major surgery in the past 4 weeks or have an organ transplant.
- Your organs (like liver, kidneys, blood) must be working acceptably.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug for people with advanced solid tumors or lymphoma that has not responded to standard treatments and has a specific genetic change (loss of MTAP or CDKN2A genes). The drug is taken by mouth and may work by targeting cancer cells with this change.
This trial tests an experimental drug called AK138D1, either by itself or combined with another drug (ivonescimab), for people with advanced non-small cell lung cancer that has spread. It aims to see if these treatments are safe and effective.
This Phase 1/2 trial tests a combination of two immune-targeting drugs (AK109 and AK104) in people with advanced solid tumors that can’t be treated with standard options, or where standard treatment didn’t work or wasn’t tolerated. It aims to find safe dosing and whether the treatment can shrink tumors or control the disease.
This trial tests a combination of two experimental drugs (LB1410 and LB4330) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments or where no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests a new drug called AK131 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and can help slow or shrink the cancer.
This trial tests a new drug called AK138D1 for people with advanced solid tumors. It aims to see if the drug is safe and how well it works, especially for tumors that haven't been treated with HER3-targeted therapy before.
Hear when a new Advanced Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.